Merck’s Keytruda Is Dealt a Legal Setback. It’s Good News for This Biotech Stock.

A Dutch court rules in favor of Halozyme Therapeutics, barring Merck from selling subcutaneous Keytruda in eight European markets. Continue Reading

阅读完整 Veytics 简报

我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。